Evidence map›Paper›PMID 30385810›Full record

ArticleScientific reports2018

Enoxacin and bis-enoxacin stimulate 4T1 murine breast cancer cells to release extracellular vesicles that inhibit osteoclastogenesis.

Taylor C Vracar, Jian Zuo, JeongSu Park, Demyana Azer, Christy Mikhael, Sophia A Holliday, Dontreyl Holsey, Guanghong Han, Lindsay VonMoss, John K Neubert and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Taylor C VracarDepartment of Orthodontics, University of Florida College of Dentistry, Gainesville, FL, 32610, USA.
Jian ZuoDepartment of Orthodontics, University of Florida College of Dentistry, Gainesville, FL, 32610, USA.
JeongSu ParkDepartment of Orthodontics, University of Florida College of Dentistry, Gainesville, FL, 32610, USA.
Demyana AzerDepartment of Orthodontics, University of Florida College of Dentistry, Gainesville, FL, 32610, USA.
Christy MikhaelDepartment of Orthodontics, University of Florida College of Dentistry, Gainesville, FL, 32610, USA.
Sophia A HollidayDepartment of Orthodontics, University of Florida College of Dentistry, Gainesville, FL, 32610, USA.
Dontreyl HolseyDepartment of Orthodontics, University of Florida College of Dentistry, Gainesville, FL, 32610, USA.
Guanghong HanDepartment of Oral Geriatrics, School and Hospital of Stomatology, Jilin University, Changchun, 130021, P. R. China.
Lindsay VonMossDepartment of Orthodontics, University of Florida College of Dentistry, Gainesville, FL, 32610, USA.
John K NeubertDepartment of Orthodontics, University of Florida College of Dentistry, Gainesville, FL, 32610, USA.
Wellington J RodyDepartment of Orthodontics, University of Florida College of Dentistry, Gainesville, FL, 32610, USA.
Edward K L ChanDepartment of Oral Biology, University of Florida College of Dentistry, Gainesville, FL, 32610, USA.
L Shannon HollidayDepartment of Orthodontics, University of Florida College of Dentistry, Gainesville, FL, 32610, USA. sholliday@dental.ufl.edu.
University of Florida · USFlorida College · USJilin University · CN

Funding

Dental applications for a novel osteoclast inhibitorR21DE019862 · NIDCR · UNIVERSITY OF FLORIDA · PI HOLLIDAY, LEXIE SHANNON · 2010 to 2011
$401k
NIDCR NIH HHS R21 DE019862
6 · The paper itself

Abstract

Enoxacin and its bone-seeking bisphosphonate derivative, bis-enoxacin, have recently captured attention as potential therapeutic agents for the treatment of cancer and bone disease. No differences in growth or survival of 4T1 murine breast cancer cells were detected at a concentration of 50 µM of enoxacin or bis-enoxacin. Growth was perturbed at higher concentrations. Both 50 µM enoxacin and bis-enoxacin stimulated increases in the number of GW/Processing bodies, but there were minimal changes in microRNA levels. Extracellular vesicles (EVs) released from 4T1 cells treated with 50 µM enoxacin or 50 µM bis-enoxacin stimulated proliferation of RAW 264.7 cells, and both significantly inhibited osteoclastogenesis in calcitriol-stimulated mouse marrow. EVs from 4T1 cells treated with enoxacin and bis-enoxacin displayed small reductions in the amount of microRNA (miR)-146a-5p and let-7b-5p. In marked contrast, miR-214-3p, which has been shown to regulate bone remodeling, was increased 22-fold and 30-fold respectively. We conclude that enoxacin and bis-enoxacin trigger the release of EVs from 4T1 cancer cells that inhibit osteoclastogenesis.

Indexed as

AnimalsBone Marrow CellsBone RemodelingBreast NeoplasmsCalcitriolCell ProliferationDiphosphonatesEnoxacinExtracellular VesiclesFemaleGene Expression Regulation, NeoplasticHumansMammary Glands, AnimalMiceMicroRNAsOsteogenesisCalcitriolDiphosphonatesEnoxacinMicroRNAsMirn146 microRNA, mouseMirn214 microRNA, mousemirnlet7 microRNA, mouse

Identifiers

PMID30385810
PMCPMC6212457
OpenAlexW2898588691

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.